| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, ... New England journal of medicine 351 (4), 337-345, 2004 | 6614 | 2004 |
| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 5016 | 2014 |
| Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer RG Amado, M Wolf, M Peeters, E Van Cutsem, S Siena, DJ Freeman, ... Journal of clinical oncology 26 (10), 1626-1634, 2008 | 4132 | 2008 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3238 | 2013 |
| Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ... New England Journal of Medicine 369 (11), 1023-1034, 2013 | 2671 | 2013 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2621 | 2010 |
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ... Journal of clinical oncology 25 (13), 1658-1664, 2007 | 2450 | 2007 |
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with … JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Journal of clinical oncology 28 (31), 4697-4705, 2010 | 2269 | 2010 |
| Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore-Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008 | 2191 | 2008 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 2088 | 2012 |
| Integrating liquid biopsies into the management of cancer G Siravegna, S Marsoni, S Siena, A Bardelli Nature reviews Clinical oncology 14 (9), 531-548, 2017 | 1899 | 2017 |
| Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial MS Brose, CM Nutting, B Jarzab, R Elisei, S Siena, L Bastholt, ... The Lancet 384 (9940), 319-328, 2014 | 1766* | 2014 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1567 | 2020 |
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005 | 1180 | 2005 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1153 | 2015 |
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ... Cancer research 67 (6), 2643-2648, 2007 | 1093 | 2007 |
| A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011 | 1043 | 2011 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 1031 | 2016 |
| Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation AM Gianni, S Siena, M Bregni, AC Stern, C Tarella, A Pileri, G Bonadonna The Lancet 334 (8663), 580-585, 1989 | 962 | 1989 |
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009 | 941 | 2009 |
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyBestätigte E-Mail-Adresse bei ospedaleniguarda.it
